For instance, the coiled-coil domain containing 6 (CCDC6) is a recurrent gene-forming fusion with RET in lung cancer, where it has shown potential druggability of EGFR inhibitors in combination with RET inhibitors, decreasing resistance to RET inhibitors while also enhancing sensitivity to PARP inhibitors (79). Here, RET is linked to lung carcinoma.